SUPPLY of LUTATHERA® (lutetium Lu 177 dotatate) and PLUVICTO™ (lutetium Lu 177 vipivotide tetraxetan)
Award
$480,120
Recipient
Novartis Pharmaceuticals Corporation
Sep 30, 2026
Key details
Notice type
Award Notice
NAICS code
—
PSC / classification
—
Set-aside
—
Place of performance
Bethesda, Maryland
Response deadline
—
Solicitation summary
Clinical Utility: It is used for targeted radioligand therapy for specific types of prostate cancer within the Nuclear Medicine Division of the Department of Radiology at WRNMMC. Novartis Pharmaceuticals Corporation is the sole source for Pluvicto. Therefore, the recommended course of action is to award a contract directly to Novartis. This approach is deemed to be in the government's best interest to ensure the seamless delivery of these critical supplies and maintain conti…
Read the full solicitation
Start free to unlock the complete notice, the contracting officer’s contact details, and every solicitation document.
Contact the contracting officer
Draft an outreach email with AI
A tailored, professional email to the contracting officer about this solicitation — written in seconds, grounded in this notice.
Free with an account · included with a WinAContract account. AI-written, grounded in this notice — review before sending.
Send it to GovCon — docs + AI brief, automatically.
We pull the solicitation files and summarize what you need to know.